secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2026-08-05T11:33:09+00:00
Accession:  0001802768-26-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q2 Royalty Receipts up 14% to $768M; raises FY 2026 guidance
---------------------------------------------------------------------------

- Q2 Royalty Receipts $768M (+14% YoY); Portfolio Receipts $773M (+6%).
- Raised FY 2026 Portfolio Receipts guidance to $3.4B-$3.5B (from $3.325B-$3.45B).
- Acquired royalty on AstraZeneca's cliramitug for up to $425M ($125M upfront) in July.
- Capital Deployment YTD $1.1B; announced transactions value $1.7B.
- Paid Q2 dividend $0.235/share; repurchased $45M in shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/0001802768-26-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001802768-26-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer